Supplementary Table 6. Multivariable models with re-specifications (prior HE+lactulose in main results)

Variable	OR (95% CI)	*P*-value
Model: prior HE only		
Outcome: DRO development		
Rifaximin on admission	1.09 (0.83–1.43)	0.527
Male	0.73 (0.58–0.92)	0.008
HBV etiology	0.65 (0.45–0.92)	0.020
MELD-Na	1.03 (1.01–1.04)	<0.001
Outcome: composite death or DRO		
Rifaximin on admission	1.34 (1.08–1.65)	0.007
Male sex	0.82 (0.68–0.98)	0.035
HBV etiology	0.59 (0.45–0.76)	<0.001
MELD-Na	1.08 (1.07–1.10)	<0.001
Model: lactulose on admission only		
Outcome: DRO development		
Rifaximin on admission	1.11 (0.84–1.47)	0.471
Male	0.73 (0.58–0.92)	0.007
HBV etiology	0.64 (0.45–0.91)	0.016
MELD-Na	1.03 (1.01–1.04)	<0.001
Outcome: composite death or DRO		
Rifaximin on admission	1.26 (1.01–1.57)	0.041
Male sex	0.81 (0.68–0.98)	0.027
Lactulose on admission	1.24 (1.01–1.52)	0.044
HBV etiology	0.58 (0.45–0.76)	<0.001
MELD-Na	1.08 (1.07–1.10)	<0.001

CI, confidence interval; DRO, drug-resistant organism; HBV, hepatitis B virus; HE, hepatic encephalopathy; MELD-Na, Model for end-stage liver disease; OR, odds ratio.

 https://doi.org/10.3350/cmh.2026.0228